An Exploratory Subgroup Analysis Of A Phase Ii/Iii Trial Of Donafenib Versus Sorafenib In The First-Line Treatment Of Advanced Hepatocellular Carcinoma

An open-label, randomized, multicentre phase II/III trial (ZGDH3) has demonstrated that compared with sorafenib, donafenib significantly prolonged the overall survival (OS) of patients with advanced hepatocellular carcinoma (HCC). It also showed a better survival benefit than sorafenib in the prespecified subgroup analysis. This article aimed to further explore whether the baseline characteristics of patients other than the predefined subgroups were related to the better OS benefit of donafenib.